

Supplemental Table S1: Summary statistics calculated from cases in review

	<b>Cases of ICI-SSc (n= 4)</b>	<b>Cases of ICI-Morphea (n= 5)</b>	<b>Cases of ICI-Eosinophilic fasciitis (n= 14)</b>
<b>Median age*</b>	66 years	53 years	56 years
<b>Malignancy types</b>	Melanoma 75% Lung 25%	Melanoma 80% Colorectal cancer 20%	Melanoma 64% Lung 21% Breast 7% Bladder 7%
<b>ICI use</b>	0%	60%	14%
Combination ICI	75%	20%	71%
Anti-PD-1	25%	0%	14%
Anti-PDL1	0%	20%	0%
Anti-PDL1 and Other			
<b>Median onset after ICI start**</b>	47 weeks	30 weeks	56 weeks
<b>Median duration of ICI- SSc**</b>	32 weeks	30 weeks	26 weeks
<b>Treatments used</b>	Steroids: 75% Hydroxychloroquine: 25% IVIg: 25% Mycophenolate: 50%	Topical steroids: 60% Systemic steroids: 60% Colchicine: 20% Cyclophosphamide: 20% Rituximab: 20% Hydroxychloroquine: 20% Calcipotriol: 20%	Systemic steroids: 93% Methotrexate: 57% Cyclosporine: 7% IVIg: 14% Abatacept: 7% Infliximab: 7% Omalizuman: 7% Mycophenolate: 14%

\*Excluding non-exact ages, \*\*When known

CTLA4: cytotoxic T-lymphocyte-associated protein 4ICI: Immune checkpoint inhibitor, ICI-SSc: Immune checkpoint inhibitor associated systemic sclerosis, PD1: Programmed cell death protein 1, PD-L1: Programmed death-ligand 1